Strontium-89 therapy: measurement of absorbed dose to skeletal metastases.
We report measurements of absorbed dose to vertebral metastases in ten patients referred for 89Sr therapy for disseminated prostatic carcinoma. Patients received a tracer dose of 85Sr at the time of 89Sr treatment and metastatic strontium retention was monitored scintigraphically for 6 mo. Metastatic 85Sr activity corrected for tissue attenuation was measured using the conjugate view principle, with special care taken to eliminate errors due to the selection of the metastatic region of interest. Metastatic volume was determined from high resolution CT images, and density inferred from Hounsfield number using the QCT bone mineral calibration of Genant and Cann. The mean absorbed dose was 850 rad/mCi (23 cGy/MBq) with a range from 220-2260 rad/mCi (6 to 61 cGy/MBq). The wide range found was consistent with the variation expected to arise due to differences in strontium renal plasma clearance (range 0.1-11.81/day) and extent of skeletal metastatic disease (varying from two small metastases to a superscan on [99mTc]MDP images) among the patients studied.
Blake
G M
GM
Wessex Regional Dept. of Nuclear Medicine, Southampton General Hospital, England.
Zivanovic
M A
MA
Blaquiere
R M
RM
Fine
D R
DR
McEwan
A J
AJ
Ackery
D M
DM
D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms; D011877:Radionuclide Imaging; D011879:Radiotherapy Dosage; D013125:Spinal Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy / Q000556:secondary*; D013131:Spine / Q000000981:diagnostic imaging; D013326:Strontium Radioisotopes / Q000627:therapeutic use*
D013326:Strontium Radioisotopes